Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
03 July 2019 | Story Leonie Bolleurs
KovsiesCare - Clean Up Read More
Tsietsi Ngobese, through the Wesolve4x Cleaning My Planet Campaign, motivated citizens to collectively fill over 23 000 refuse bags to date.

The mission: To collectively fill 20 million refuse bags every Saturday with the help of 20 million people who are cleaning their own communities and our planet for an hour. The message: My planet, my responsibility.

The mission and message that the Wesolve4x Cleaning My Planet Campaign wants to convey, is based on a simple premise: Get community members to donate one hour of their time to cleaning duties every Saturday for the next 20 years until 2039. At the same time provide a continuous educational programme about waste management to the general public and to schools in order to empower them to take responsibility.

Address trash blindness


Tsietsi Ngobese, Chief Executive Officer of this initiative and BSc Actuarial Science graduate, says he understands the transformative power of education and the role it plays in transforming diverse communities. Through outreach programmes in our community and schools, we are slowly eliminating generational trash blindness. We also tackle some of the social determinants of health by encouraging healthy living conditions within our communities through good waste management and recycling. 

It is important for Tsietsi to add value to society. He believes that the Wesolve4x Generation will transform the world for the better through education and empowering all citizens.

The campaign – officially endorsed by Miss Earth South Africa, Catherine Constantinides – was launched on the UFS Bloemfontein Campus as well as the Abram Hlope Primary School in Katlehong on 4 May 2019.

“We want to promote the benefits of a clean and healthy environment for future generations,” said Tsietsi. 

Since their inception, the group has collectively filled over 23 000 refuse bags with the help of active citizens. 

Challenge accepted

When former lecturer, Jan Blomerus, once challenged his Actuarial students to protect the environment in order to decrease the mortality rate (from natural disasters because of the effect of climate change), Tsietsi accepted the challenge. “By inspiring excellence and transforming lives, the UFS plays an important role; I started to believe that I can address societal challenges in the communities I am an integral part of,” he said.

When Tsietsi saw trash piling up everywhere and children playing at illegal dumping sites, he became concerned about the health risk to society. He believes the dumping area is contaminating the air and water around the dumping site. 

“I had to be part of the solution to start cleaning up, and most importantly, educating myself and others to continuously take responsibility for our own waste and change our thinking about littering. This is a generational issue and needs a generational approach to unlearn all habits of littering,” Tsietsi pointed out. 

As part of his vision, Tsietsi plans to reduce the waste taken to landfill sites and to increase that which is taken directly from households to recycling plants. He also wants to encourage people to find creative ways of converting what has previously been wasted into something useful. “This action can encourage individuals to generate an income from waste,” he said.

Take action

Tsietsi invites all members of the Mangaung community to get involved in the project. This is your opportunity to make a difference on Mandela Day. You can;
provide sponsorship for educational content on effective waste management, economic opportunities, and health issues to the general public and to schools;
provide refuse bags, plastic gloves or hand-washing soap (used by community members in every clean-up session);
join in a collective effort to clean your community by meeting at designated schools or any designated community assembly point on a Saturday (contact 011 307 2005 or info@wesolve4x.com for more information).


News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept